KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Current Assets (2016 - 2025)

Historic Current Assets for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $5.7 billion.

  • BeOne Medicines' Current Assets rose 4480.72% to $5.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year increase of 4480.72%. This contributed to the annual value of $4.0 billion for FY2024, which is 503.93% down from last year.
  • BeOne Medicines' Current Assets amounted to $5.7 billion in Q3 2025, which was up 4480.72% from $4.3 billion recorded in Q2 2025.
  • BeOne Medicines' Current Assets' 5-year high stood at $7.6 billion during Q4 2021, with a 5-year trough of $3.1 billion in Q4 2022.
  • In the last 5 years, BeOne Medicines' Current Assets had a median value of $4.4 billion in 2023 and averaged $4.8 billion.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 5348.43% in 2021, then plummeted by 5932.93% in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Current Assets stood at $7.6 billion in 2021, then tumbled by 59.33% to $3.1 billion in 2022, then surged by 35.74% to $4.2 billion in 2023, then fell by 5.04% to $4.0 billion in 2024, then soared by 41.91% to $5.7 billion in 2025.
  • Its last three reported values are $5.7 billion in Q3 2025, $4.3 billion for Q2 2025, and $3.9 billion during Q1 2025.